Abstract session: Immunity and Hepatocellular Carcinoma

 Liver tumours

Room 2
English
Abstract session
27 August 2020 11:00 - 12:30


Presentations

Title Time

Add to Calendar

AS049 Identification of a panel of safe immunogenic antigens for therapeutic vaccination strategies in hepatocellular carcinoma
27 August 2020 11:00 - 11:15
AS050 Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma
27 August 2020 11:15 - 11:30
AS051 Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy
27 August 2020 11:30 - 11:45
AS052* PD1hi CD103+ CD8+ T cells with exhausted-like TRM features promote tumor progression but predict a favorable response to anti-PD1 treatment in hepatocellular carcinoma
27 August 2020 11:45 - 12:00
AS053 Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma
27 August 2020 12:00 - 12:15
AS054 Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy.
27 August 2020 12:15 - 12:30